Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial

T. Drayson, Mark; Bowcock, Stella; Planche, Tim; Iqbal, Gulnaz; Pratt, Guy; Yong, Kwee; Wood, Jill; Raynes, Kerry; Higgins, Helen; Dawkins, Bryony; Meads, David; Hulme, Claire; M. Monahan, Irene; Karunanithi, Kamaraj; Dignum, Helen; Belsham, Edward; Neilson, Jeff; Harrison, Beth; Lokare, Anand; Campbell, Gavin; R. Hamblin, Michael; M. Hawkey, Peter; C Whittaker, Anna; Low, Eric; Dunn, Janet

doi:10.1016/s1470-2045(19)30506-6

Public

Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial

Published in The Lancet Oncology • Oct 23, 2019

Authors:

Mark T. Drayson

Stella Bowcock

Tim Planche

Abstract

BACKGROUND: Myeloma causes profound immunodeficiency and recurrent, serious infections. Around 5500 new cases of myeloma are diagnosed per year in the UK, and a quarter of patients will have a serious infection within 3 months of diagnosis. We aimed to assess whether patients newly diagnosed with my...

Subject

Medicine

Double blind

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!